Skip to main content
SpringerLink
Log in

Patent Ductus Arteriosus: The Conundrum and Management Options

  • Chapter
  • First Online:
Emerging Topics and Controversies in Neonatology

  • 815 Accesses

Abstract

Patency of the ductus arteriosus (PDA) in preterm infants is associated with increased morbidity and mortality. However, there has been growing controversy regarding the approach to its management. Various medical treatment approaches thus far have failed to demonstrate any improvement in clinical outcomes such as necrotising enterocolitis, bronchopulmonary dysplasia or death, and surgical closure has been associated with neurodevelopmental impairment. This has led to uncertainty about whether to treat or not to treat a PDA, and an increasing number of clinicians are following a more conservative approach of a “wait and watch” policy due to uncertainty. Clinicians with hemodynamic interest are however concerned about the side effects of persistent PDA. With the availability of bedside echocardiography, they have started assessing the PDA before it is symptomatic in the first 2–3 days and commencing medical treatment in a select population of extremely preterm babies who are at highest risk of complications due to persistent PDA. Other biomarkers are also studied to identify PDA that might benefit from closure. The oral route of ibuprofen administration has also been explored with promising early results suggesting improved efficacy in closure of PDA in a select population. With concerns about surgical ligation, newer techniques such as percutaneous trans-venous device closure are now being used, as small devices are now available that can be used in babies as small as 700 g.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Schmidt B, Davis P, Moddemann D, Ohlsson A, Roberts RS, Saigal S, et al. Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. N Engl J Med. 2001;344(26):1966–72.

    Article  CAS  PubMed  Google Scholar 

  2. Sellmer A, Bjerre JV, Schmidt MR, McNamara PJ, Hjortdal VE, Host B, et al. Morbidity and mortality in preterm neonates with patent ductus arteriosus on day 3. Arch Dis Child Fetal Neonatal Ed. 2013;98(6):F505–10.

    Article  PubMed  Google Scholar 

  3. Noori S, McCoy M, Friedlich P, Bright B, Gottipati V, Seri I, et al. Failure of ductus arteriosus closure is associated with increased mortality in preterm infants. Pediatrics. 2009;123(1):e138–44.

    Article  PubMed  Google Scholar 

  4. Janz-Robinson EM, Badawi N, Walker K, Bajuk B, Abdel-Latif ME. Neurodevelopmental outcomes of premature infants treated for patent ductus arteriosus: a population-based cohort study. J Pediatr. 2015;167(5):1025–32.e3.

    Article  PubMed  Google Scholar 

  5. Kluckow M, Jeffery M, Gill A, Evans N. A randomised placebo-controlled trial of early treatment of the patent ductus arteriosus. Arch Dis Child Fetal Neonatal Ed. 2014;99(2):F99–F104.

    Article  PubMed  Google Scholar 

  6. Aranda JV, Clyman R, Cox B, Van Overmeire B, Wozniak P, Sosenko I, et al. A randomized, double-blind, placebo-controlled trial on intravenous ibuprofen L-lysine for the early closure of nonsymptomatic patent ductus arteriosus within 72 hours of birth in extremely low-birth-weight infants. Am J Perinatol. 2009;26(3):235–45.

    Article  PubMed  Google Scholar 

  7. Bixler GM, Powers GC, Clark RH, Walker MW, Tolia VN. Changes in the diagnosis and management of patent ductus arteriosus from 2006 to 2015 in United States neonatal intensive care units. J Pediatr. 2017;189:105–12.

    Article  PubMed  Google Scholar 

  8. Edstedt Bonamy AK, Gudmundsdottir A, Maier RF, Toome L, Zeitlin J, Bonet M, et al. Patent ductus arteriosus treatment in very preterm infants: a European Population-Based Cohort Study (EPICE) on variation and outcomes. Neonatology. 2017;111(4):367–75.

    Article  PubMed  Google Scholar 

  9. Polat TB, Celik IH, Erdeve O. Early predictive echocardiographic features of hemodynamically significant patent ductus arteriosus in preterm VLBW infants. Pediatr Int. 2016;58(7):589–94.

    Article  PubMed  Google Scholar 

  10. Lee A, Nestaas E, Liestol K, Brunvand L, Lindemann R, Fugelseth D. Tissue Doppler imaging in very preterm infants during the first 24 h of life: an observational study. Arch Dis Child Fetal Neonatal Ed. 2014;99(1):F64–9.

    Article  CAS  PubMed  Google Scholar 

  11. Helfer S, Schmitz L, Buhrer C, Czernik C. Tissue Doppler-derived strain and strain rate during the first 28 days of life in very low birth weight infants. Echocardiography. 2014;31(6):765–72.

    Article  PubMed  Google Scholar 

  12. van Laere D, van Overmeire B, Gupta S, El Khuffash A, Savoia M, McNamara PJ, et al. Application of NPE in the assessment of a patent ductus arteriosus. Pediatr Res. 2018;84(Suppl 1):46–56.

    Article  PubMed  PubMed Central  Google Scholar 

  13. de Waal K, Phad N, Collins N, Boyle A. Cardiac remodeling in preterm infants with prolonged exposure to a patent ductus arteriosus. Congenit Heart Dis. 2017;12(3):364–72.

    Article  PubMed  Google Scholar 

  14. El-Khuffash AF, Jain A, Weisz D, Mertens L, McNamara PJ. Assessment and treatment of post patent ductus arteriosus ligation syndrome. J Pediatr. 2014;165(1):46–52.e1.

    Article  CAS  PubMed  Google Scholar 

  15. El-Khuffash AF, Jain A, Dragulescu A, McNamara PJ, Mertens L. Acute changes in myocardial systolic function in preterm infants undergoing patent ductus arteriosus ligation: a tissue Doppler and myocardial deformation study. J Am Soc Echocardiogr. 2012;25(10):1058–67.

    Article  PubMed  Google Scholar 

  16. Rodriguez Sanchez de la Blanca A, Sanchez Luna M, Gonzalez Pacheco N, Arriaga Redondo M, Navarro Patino N. Electrical velocimetry for non-invasive monitoring of the closure of the ductus arteriosus in preterm infants. Eur J Pediatr. 2018;177(2):229–35.

    Article  PubMed  Google Scholar 

  17. Chock VY, Rose LA, Mante JV, Punn R. Near-infrared spectroscopy for detection of a significant patent ductus arteriosus. Pediatr Res. 2016;80(5):675–80.

    Article  PubMed  Google Scholar 

  18. Chock VY, Ramamoorthy C, Van Meurs KP. Cerebral oxygenation during different treatment strategies for a patent ductus arteriosus. Neonatology. 2011;100(3):233–40.

    Article  CAS  PubMed  Google Scholar 

  19. Gomez-Pomar E, Makhoul M, Westgate PM, Ibonia KT, Patwardhan A, Giannone PJ, et al. Relationship between perfusion index and patent ductus arteriosus in preterm infants. Pediatr Res. 2017;81(5):775–9.

    Article  PubMed  Google Scholar 

  20. Terek D, Altun Koroglu O, Ulger Z, Yalaz M, Kultursay N. The serial changes of perfusion index in preterm infants with patent ductus arteriosus: is perfusion index clinically significant? Minerva Pediatr. 2016;68(4):250–5.

    PubMed  Google Scholar 

  21. Weisz DE, McNamara PJ, El-Khuffash A. Cardiac biomarkers and haemodynamically significant patent ductus arteriosus in preterm infants. Early Hum Dev. 2017;105:41–7.

    Article  PubMed  Google Scholar 

  22. Kalra VK, DeBari VA, Zauk A, Kataria P, Myridakis D, Kiblawi F. Point-of-care testing for B-type natriuretic peptide in premature neonates with patent ductus arteriosus. Ann Clin Lab Sci. 2011;41(2):131–7.

    CAS  PubMed  Google Scholar 

  23. El-Khuffash AF, Slevin M, McNamara PJ, Molloy EJ. Troponin T, N-terminal pro natriuretic peptide and a patent ductus arteriosus scoring system predict death before discharge or neurodevelopmental outcome at 2 years in preterm infants. Arch Dis Child Fetal Neonatal Ed. 2011;96(2):F133–7.

    Article  PubMed  Google Scholar 

  24. Harris SL, More K, Dixon B, Troughton R, Pemberton C, Horwood J, et al. Factors affecting N-terminal pro-B-type natriuretic peptide levels in preterm infants and use in determination of haemodynamic significance of patent ductus arteriosus. Eur J Pediatr. 2018;177(4):521–32.

    Article  CAS  PubMed  Google Scholar 

  25. Czernik C, Metze B, Muller C, Buhrer C. Urinary NT-proBNP and ductal closure in preterm infants. J Perinatol. 2013;33(3):212–7.

    Article  CAS  PubMed  Google Scholar 

  26. El-Khuffash A, Barry D, Walsh K, Davis PG, Molloy EJ. Biochemical markers may identify preterm infants with a patent ductus arteriosus at high risk of death or severe intraventricular haemorrhage. Arch Dis Child Fetal Neonatal Ed. 2008;93(6):F407–12.

    Article  CAS  PubMed  Google Scholar 

  27. Meinarde L, Hillman M, Rizzotti A, Basquiera AL, Tabares A, Cuestas E. C-reactive protein, platelets, and patent ductus arteriosus. Platelets. 2016;27(8):821–3.

    Article  CAS  PubMed  Google Scholar 

  28. Temel MT, Coskun ME, Akbayram S, Demiryurek AT. Association between neutrophil/lymphocyte ratio with ductus arteriosus patency in preterm newborns. Bratisl Lek Listy. 2017;118(8):491–4.

    CAS  PubMed  Google Scholar 

  29. Simon SR, van Zogchel L, Bas-Suarez MP, Cavallaro G, Clyman RI, Villamor E. Platelet counts and patent ductus arteriosus in preterm infants: a systematic review and meta-analysis. Neonatology. 2015;108(2):143–51.

    Article  CAS  PubMed  Google Scholar 

  30. Demir N, Peker E, Ece I, Agengin K, Bulan KA, Tuncer O. Is platelet mass a more significant indicator than platelet count of closure of patent ductus arteriosus? J Matern Fetal Neonatal Med. 2016;29(12):1915–8.

    PubMed  Google Scholar 

  31. Bin-Nun A, Mimouni FB, Fink D, Sela H, Hammerman C. Elevated nucleated red blood cells at birth predict hemodynamically significant patent ductus arteriosus. J Pediatr. 2016;177:313–5.

    Article  PubMed  Google Scholar 

  32. Evans N. Preterm patent ductus arteriosus: a continuing conundrum for the neonatologist? Semin Fetal Neonatal Med. 2015;20(4):272–7.

    Article  PubMed  Google Scholar 

  33. Letshwiti JB, Semberova J, Pichova K, Dempsey EM, Franklin OM, Miletin J. A conservative treatment of patent ductus arteriosus in very low birth weight infants. Early Hum Dev. 2017;104:45–9.

    Article  CAS  PubMed  Google Scholar 

  34. Cassady G, Crouse DT, Kirklin JW, Strange MJ, Joiner CH, Godoy G, et al. A randomized, controlled trial of very early prophylactic ligation of the ductus arteriosus in babies who weighed 1000 g or less at birth. N Engl J Med. 1989;320(23):1511–6.

    Article  CAS  PubMed  Google Scholar 

  35. Bell EF, Acarregui MJ. Restricted versus liberal water intake for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev. 2014;(12):CD000503.

    Google Scholar 

  36. De Buyst J, Rakza T, Pennaforte T, Johansson AB, Storme L. Hemodynamic effects of fluid restriction in preterm infants with significant patent ductus arteriosus. J Pediatr. 2012;161(3):404–8.

    Article  PubMed  Google Scholar 

  37. Takami T, Yoda H, Ishida T, Morichi S, Kondo A, Sunohara D, et al. Effects of indomethacin on patent ductus arteriosus in neonates with genetic disorders and/or congenital anomalies. Am J Perinatol. 2013;30(7):551–6.

    PubMed  Google Scholar 

  38. Brion LP, Campbell DE. Furosemide for symptomatic patent ductus arteriosus in indomethacin-treated infants. Cochrane Database Syst Rev. 2001;(3):CD001148.

    Google Scholar 

  39. Lee BS, Byun SY, Chung ML, Chang JY, Kim HY, Kim EA, et al. Effect of furosemide on ductal closure and renal function in indomethacin-treated preterm infants during the early neonatal period. Neonatology. 2010;98(2):191–9.

    Article  CAS  PubMed  Google Scholar 

  40. Thomson EJ, Greenberg RG, Kumar K, Laughon M, Smith PB, Clark RH, et al. Association between furosemide exposure and patent ductus arteriosus in hospitalized infants of very low birth weight. J Pediatr. 2018;199:231–6.

    Article  CAS  Google Scholar 

  41. Flannery DD, O’Donnell E, Kornhauser M, Dysart K, Greenspan J, Aghai ZH. Continuous positive airway pressure versus mechanical ventilation on the first day of life in very low-birth-weight infants. Am J Perinatol. 2016;33(10):939–44.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Lodha A, Seshia M, McMillan DD, Barrington K, Yang J, Lee SK, et al. Association of early caffeine administration and neonatal outcomes in very preterm neonates. JAMA Pediatr. 2015;169(1):33–8.

    Article  PubMed  Google Scholar 

  43. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, et al. Caffeine therapy for apnea of prematurity. N Engl J Med. 2006;354(20):2112–21.

    Article  CAS  PubMed  Google Scholar 

  44. Barefield ES, Dwyer MD, Cassady G. Association of patent ductus arteriosus and phototherapy in infants weighing less than 1000 grams. J Perinatol. 1993;13(5):376–80.

    CAS  PubMed  Google Scholar 

  45. Surmeli-Onay O, Yurdakok M, Karagoz T, Erkekoglu P, Ertugrul I, Takci S, et al. A new approach to an old hypothesis; phototherapy does not affect ductal patency via PGE2 and PGI2. J Matern Fetal Neonatal Med. 2015;28(1):16–22.

    Article  CAS  PubMed  Google Scholar 

  46. Mannan J, Amin SB. Meta-analysis of the effect of chest shielding on preventing patent ductus arteriosus in premature infants. Am J Perinatol. 2017;34(4):359–63.

    Article  PubMed  Google Scholar 

  47. Nelin TD, Pena E, Giacomazzi T, Lee S, Logan JW, Moallem M, et al. Outcomes following indomethacin prophylaxis in extremely preterm infants in an all-referral NICU. J Perinatol. 2017;37(8):932–7.

    Article  CAS  PubMed  Google Scholar 

  48. Mirza H, Laptook AR, Oh W, Vohr BR, Stoll BJ, Kandefer S, et al. Effects of indomethacin prophylaxis timing on intraventricular haemorrhage and patent ductus arteriosus in extremely low birth weight infants. Arch Dis Child Fetal Neonatal Ed. 2016;101(5):F418–22.

    Article  PubMed  Google Scholar 

  49. Kalani M, Shariat M, Khalesi N, Farahani Z, Ahmadi S. A comparison of early ibuprofen and indomethacin administration to prevent Intraventricular hemorrhage among preterm infants. Acta Med Iran. 2016;54(12):788–92.

    PubMed  Google Scholar 

  50. Fanos V, Pusceddu M, Dessi A, Marcialis MA. Should we definitively abandon prophylaxis for patent ductus arteriosus in preterm new-borns? Clinics (Sao Paulo). 2011;66(12):2141–9.

    Article  Google Scholar 

  51. Juarez-Dominguez G, Iglesias-Leboreiro J, Rendon-Macias ME, Bernardez-Zapata I, Patino-Bahena EJ, Agami-Micha S, et al. [Echocardiographic screening vs. symptomatic diagnosis for patent ductus arteriosus in preterms]. Rev Med Inst Mex Seguro Soc. 2015;53(2):136–41.

    Google Scholar 

  52. Clyman RI. The role of patent ductus arteriosus and its treatments in the development of bronchopulmonary dysplasia. Semin Perinatol. 2013;37(2):102–7.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Gupta S, McNamara P. Contemporary approach to the patent ductus arteriosus and future considerations. Semin Fetal Neonatal Med. 2018;23(4):223–4.

    Article  PubMed  Google Scholar 

  54. Pourarian S, Sharma D, Farahbakhsh N, Cheriki S, Bijanzadeh F. To evaluate the prevalence of symptomatic and non-symptomatic ductus arteriosus and accuracy of physical signs in diagnosing PDA in preterm infants using blinded comparison of clinical and echocardiographic findings during the first week of life: a prospective observational study from Iran. J Matern Fetal Neonatal Med. 2017;30(14):1666–70.

    Article  PubMed  Google Scholar 

  55. Malviya MN, Ohlsson A, Shah SS. Surgical versus medical treatment with cyclooxygenase inhibitors for symptomatic patent ductus arteriosus in preterm infants. Cochrane Database Syst Rev. 2013;(3):CD003951.

    Google Scholar 

  56. Friedman WF, Hirschklau MJ, Printz MP, Pitlick PT, Kirkpatrick SE. Pharmacologic closure of patent ductus arteriosus in the premature infant. N Engl J Med. 1976;295(10):526–9.

    Article  CAS  PubMed  Google Scholar 

  57. Malikiwi A, Roufaeil C, Tan K, Sehgal A. Indomethacin vs ibuprofen: comparison of efficacy in the setting of conservative therapeutic approach. Eur J Pediatr. 2015;174(5):615–20.

    Article  CAS  PubMed  Google Scholar 

  58. Yadav S, Agarwal S, Maria A, Dudeja A, Dubey NK, Anand P, et al. Comparison of oral ibuprofen with oral indomethacin for PDA closure in Indian preterm neonates: a randomized controlled trial. Pediatr Cardiol. 2014;35(5):824–30.

    Article  PubMed  Google Scholar 

  59. Van Overmeire B, Follens I, Hartmann S, Creten WL, Van Acker KJ. Treatment of patent ductus arteriosus with ibuprofen. Arch Dis Child Fetal Neonatal Ed. 1997;76(3):F179–84.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Ohlsson A, Walia R, Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants. Cochrane Database Syst Rev. 2015;(2):CD003481.

    Google Scholar 

  61. Dornelles LV, Corso AL, Silveira Rde C, Procianoy RS. Comparison of two dose regimens of ibuprofen for the closure of patent ductus arteriosus in preterm newborns. J Pediatr. 2016;92(3):314–8.

    Article  Google Scholar 

  62. Mitra S, Florez ID, Tamayo ME, Mbuagbaw L, Vanniyasingam T, Veroniki AA, et al. Association of placebo, indomethacin, ibuprofen, and acetaminophen with closure of hemodynamically significant patent ductus arteriosus in preterm infants: a systematic review and meta-analysis. JAMA. 2018;319(12):1221–38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Olukman O, Calkavur S, Ercan G, Atlihan F, Oner T, Tavli V, et al. Comparison of oral and intravenous ibuprofen for medical closure of patent ductus arteriosus: which one is better? Congenit Heart Dis. 2012;7(6):534–43.

    Article  PubMed  Google Scholar 

  64. Sarici SU, Dabak O, Erdinc K, Okutan V, Lenk MK. An unreported complication of intravenously administered ibuprofen: gastrointestinal bleeding. Eur Rev Med Pharmacol Sci. 2012;16(3):325–7.

    CAS  PubMed  Google Scholar 

  65. Hammerman C, Bin-Nun A, Markovitch E, Schimmel MS, Kaplan M, Fink D. Ductal closure with paracetamol: a surprising new approach to patent ductus arteriosus treatment. Pediatrics. 2011;128(6):e1618–21.

    Article  PubMed  Google Scholar 

  66. Ohlsson A, Shah PS. Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants. Cochrane Database Syst Rev. 2018;4:CD010061.

    Google Scholar 

  67. Oncel MY, Eras Z, Uras N, Canpolat FE, Erdeve O, Oguz SS. Neurodevelopmental outcomes of preterm infants treated with oral paracetamol versus ibuprofen for patent ductus arteriosus. Am J Perinatol. 2017;34(12):1185–9.

    Article  PubMed  Google Scholar 

  68. Louis D, Torgalkar R, Shah J, Shah PS, Jain A. Enteral feeding during indomethacin treatment for patent ductus arteriosus: association with gastrointestinal outcomes. J Perinatol. 2016;36(7):544–8.

    Article  CAS  PubMed  Google Scholar 

  69. Mirea L, Sankaran K, Seshia M, Ohlsson A, Allen AC, Aziz K, et al. Treatment of patent ductus arteriosus and neonatal mortality/morbidities: adjustment for treatment selection bias. J Pediatr. 2012;161(4):689–94.e1.

    Article  PubMed  Google Scholar 

  70. Youn Y, Moon CJ, Lee JY, Lee C, Sung IK. Timing of surgical ligation and morbidities in very low birth weight infants. Medicine. 2017;96(14):e6557.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Sung SI, Chang YS, Chun JY, Yoon SA, Yoo HS, Ahn SY, et al. Mandatory closure versus nonintervention for patent ductus arteriosus in very preterm infants. J Pediatr. 2016;177:66–71.e1.

    Article  PubMed  Google Scholar 

  72. Weisz DE, Mirea L, Rosenberg E, Jang M, Ly L, Church PT, et al. Association of patent ductus arteriosus ligation with death or neurodevelopmental impairment among extremely preterm infants. JAMA Pediatr. 2017;171(5):443–9.

    Article  PubMed  PubMed Central  Google Scholar 

  73. Weisz DE, More K, McNamara PJ, Shah PS. PDA ligation and health outcomes: a meta-analysis. Pediatrics. 2014;133(4):e1024–46.

    Article  PubMed  Google Scholar 

  74. Hallik M, Tasa T, Starkopf J, Metsvaht T. Dosing of milrinone in preterm neonates to prevent postligation cardiac syndrome: simulation study suggests need for bolus infusion. Neonatology. 2017;111(1):8–11.

    Article  CAS  PubMed  Google Scholar 

  75. Jabbour J, Uhing M, Robey T. Vocal fold paralysis in preterm infants: prevalence and analysis of risk factors. J Perinatol. 2017;37(5):585–90.

    Article  CAS  PubMed  Google Scholar 

  76. Hsu KH, Chiang MC, Lien R, Chu JJ, Chang YS, Chu SM, et al. Diaphragmatic paralysis among very low birth weight infants following ligation for patent ductus arteriosus. Eur J Pediatr. 2012;171(11):1639–44.

    Article  PubMed  Google Scholar 

  77. Kim D, Kim SW, Shin HJ, Hong JM, Lee JH, Han HS. Unintended pulmonary artery ligation during PDA ligation. Heart Surg Forum. 2016;19(4):E187–8.

    Article  PubMed  Google Scholar 

  78. Resende MH, More K, Nicholls D, Ting J, Jain A, McNamara PJ. The impact of a dedicated patent ductus arteriosus ligation team on neonatal health-care outcomes. J Perinatol. 2016;36(6):463–8.

    Article  CAS  PubMed  Google Scholar 

  79. Morville P, Akhavi A. Transcatheter closure of hemodynamic significant patent ductus arteriosus in 32 premature infants by amplatzer ductal occluder additional size-ADOIIAS. Catheter Cardiovasc Interv. 2017;90(4):612–7.

    Article  PubMed  Google Scholar 

  80. Morville P, Douchin S, Bouvaist H, Dauphin C. Transcatheter occlusion of the patent ductus arteriosus in premature infants weighing less than 1200 g. Arch Dis Child Fetal Neonatal Ed. 2018;103(3):F198–f201.

    Article  PubMed  Google Scholar 

  81. Dedeoglu R, Bilici M, Demir F, Demir F, Acar OC, Hallioglu O, et al. Short-term outcomes of patent ductus arteriosus closure with new Occlutech(R) duct occluder: a multicenter study. J Interv Cardiol. 2016;29(3):325–31.

    Article  PubMed  Google Scholar 

  82. Zanjani KS, Sobhy R, El-Kaffas R, El-Sisi A. Multicenter off-label use of nit-occlud coil in retrograde closure of small patent ductus arteriosus. Pediatr Cardiol. 2017;38(4):828–32.

    Article  PubMed  Google Scholar 

  83. Wang-Giuffre EW, Breinholt JP. Novel use of the medtronic micro vascular plug for PDA closure in preterm infants. Catheter Cardiovasc Interv. 2017;89(6):1059–65.

    Article  PubMed  Google Scholar 

  84. Sathanandam S, Justino H, Waller BR 3rd, Radtke W, Qureshi AM. Initial clinical experience with the Medtronic micro vascular plug in transcatheter occlusion of PDAs in extremely premature infants. Catheter Cardiovasc Interv. 2017;89(6):1051–8.

    Article  PubMed  Google Scholar 

  85. Patel PM, Momany AM, Schaa KL, Romitti PA, Druschel C, Cooper ME, et al. Genetic modifiers of patent ductus arteriosus in term infants. J Pediatr. 2016;176:57–61.e1.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Conflict of Interest

Professor Samir Gupta is recipient of NIHR-HTA award for the Baby-OSCAR trial as chief investigator assessing early targeted treatment of PDA using ibuprofen.

Author information

Authors and Affiliations

  1. Division of Neonatology, Sidra Medicine, Doha, Qatar

    Kiran More & Samir Gupta

  2. Durham University, Stockton-on-Tees, UK

    Samir Gupta

Authors
  1. Kiran More
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Samir Gupta
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Samir Gupta .

Editor information

Editors and Affiliations

  1. Department of Health Sciences, George Davies Centre for Medicine, University of Leicester, Leicester, UK

    Elaine M. Boyle

  2. Department of Health Sciences, George Davies Centre for Medicine, University of Leicester, Leicester, UK

    Jonathan Cusack

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

More, K., Gupta, S. (2020). Patent Ductus Arteriosus: The Conundrum and Management Options. In: Boyle, E., Cusack, J. (eds) Emerging Topics and Controversies in Neonatology. Springer, Cham. https://doi.org/10.1007/978-3-030-28829-7_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-28829-7_14

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-28828-0

  • Online ISBN: 978-3-030-28829-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation